Trials / No Longer Available
No Longer AvailableNCT05686564
Early Access Program for ALXN1840 in Patients With Wilson Disease
- Status
- No Longer Available
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- Alexion Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 3 Years
- Healthy volunteers
- —
Summary
This is an open-label, single-arm, multi-center EAP, designed to provide early access to ALXN1840 for eligible patients with WD.
Detailed description
To provide access to ALXN1840 treatment, an investigational medicinal product (IMP) that has not yet been granted marketing authorization, to participants who complete Studies ALXN1840-WD-205, WTX101-301, or ALXN1840-WD-302, or other studies with ALXN1840 who, in the opinion of the Treating Physician, may benefit from continued treatment with ALXN1840, and who meet the eligibility criteria described in this protocol.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ALXN1840 | bis-choline tetrathiomolybdate |
Timeline
- First posted
- 2023-01-17
- Last updated
- 2023-05-17
Source: ClinicalTrials.gov record NCT05686564. Inclusion in this directory is not an endorsement.